"Serine Endopeptidases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
| Descriptor ID |
D012697
|
| MeSH Number(s) |
D08.811.277.656.300.760 D08.811.277.656.959.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Serine Endopeptidases".
Below are MeSH descriptors whose meaning is more specific than "Serine Endopeptidases".
This graph shows the total number of publications written about "Serine Endopeptidases" by people in this website by year, and whether "Serine Endopeptidases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2013 | 3 | 1 | 4 |
| 2014 | 1 | 4 | 5 |
| 2015 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serine Endopeptidases" by people in Profiles.
-
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
-
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 01; 36(17):1012-22.
-
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
-
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
-
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
-
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 08; 63(13):1278-1288.
-
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014; 65:417-31.
-
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14; 129(2):234-43.
-
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 05; 128(19):2113-20.
-
Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man. Circulation. 2013 Jun 18; 127(24):2372-4.